Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA CA 22 004

Frequently Asked Questions (FAQs)

What is the name of this NIH funding opportunity?

The funding opportunity is titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)."

What is the Funding Opportunity Number (FOA number)?

The Funding Opportunity Number is RFA-CA-22-004.

What CFDA number is associated with this opportunity?

The opportunity lists CFDA 93.394.

What is the main goal of this FOA?

The main goal is to support projects that advance promising biospecimen science technologies beyond early proof-of-concept and into stronger development and validation, specifically to improve the quality, consistency, and downstream usefulness of biospecimens used in cancer research and clinical care.

What types of problems is NIH trying to solve with this program?

The program targets pre-analytical problems that occur before analysis begins, such as degradation or alteration of analytes (DNA, RNA, proteins, metabolites, and other molecular markers) during specimen collection, processing, handling, transport, and storage. These issues can introduce noise, bias, and irreproducible results across studies and clinical settings.

What does "pre-analytical variability" mean in the context of this FOA?

In this FOA, pre-analytical variability refers to differences in how biospecimens are collected, processed, handled, transported, and stored, including effects from time, temperature, handling steps, and storage duration. These differences can change specimen integrity and affect downstream results.

What NIH funding mechanism is used, and what does it imply?

This FOA uses the NIH R33 mechanism. It implies the project should already have encouraging preliminary data and have cleared major feasibility hurdles, but still requires refinement and rigorous validation to be convincing and adoptable by the broader community.

What stage of technology development is NIH looking for under an R33?

NIH is looking for technologies that are beyond the earliest experimental phase (past early proof-of-concept) but not yet fully mature or widely deployable. The emphasis is on robust development and validation under realistic conditions.

What kinds of technologies are in scope for this FOA?

The scope includes tools, devices, instrumentation, and supporting methods that either preserve/protect sample integrity or enable objective verification of sample quality through clear quality assessment and quality control (QA/QC) criteria.

What does the FOA mean by technologies that "preserve or protect sample integrity"?

These are approaches intended to minimize or standardize the impacts of factors like time, temperature, handling steps, transport conditions, or storage duration that commonly drive pre-analytical changes in biospecimens.

What does the FOA mean by technologies that "verify sample quality"?

These are approaches that measure or interrogate biospecimen quality so researchers and clinicians can determine whether a specimen is fit for a specific downstream use, using objective criteria and QA/QC metrics.

What are examples of downstream uses mentioned in the FOA?

The FOA mentions downstream uses such as sequencing, proteomics, biomarker testing, and other analytic platforms.

What is the overarching expected impact of the funded work?

The expected impact is to maximize the utility of biospecimens and increase confidence that biological signals observed in research and clinical testing reflect true biology rather than artifacts introduced during collection and handling.

How does this FOA aim to improve research reproducibility?

By reducing pre-analytical variability and validating technologies under realistic, varied conditions, the FOA aims to improve comparability across labs, institutions, and studies and reduce noise and bias that can lead to irreproducible results.

What does NIH mean by validating performance under "realistic and varied conditions"?

It means the technology should demonstrate performance, robustness, and reliability in conditions that reflect real-world use rather than only ideal laboratory circumstances.

What cancer research and clinical areas does NIH connect to this program?

NIH positions this program as accelerating and improving basic cancer biology, early detection and screening, clinical diagnosis, treatment-related research, and epidemiology.

How does this FOA relate to biomarker discovery and validation?

By improving biospecimen quality and reducing pre-analytical variation, the technologies supported are expected to enable more reliable biomarker discovery and validation and improve comparability across studies and sites.

Does the FOA emphasize cancer health disparities?

Yes. The FOA emphasizes relevance to cancer health disparities, including proposals that help ensure biospecimen quality across diverse populations, settings, and resource environments, especially where collection conditions may vary systematically.

Are clinical trials allowed under this announcement?

No. Clinical trials are not allowed under this FOA.

If clinical trials are not allowed, can a project still use human biospecimens?

Yes. Work involving human biospecimens may still be relevant, but the intent is to validate technology performance characteristics, quality metrics, and operational robustness rather than conduct an interventional clinical trial that assigns participants to evaluate clinical outcomes.

Who is eligible to apply?

Eligibility is broad and includes many organization types, including state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities.

Does the FOA encourage participation from specific institution types?

Yes. The FOA explicitly highlights Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, eligible federal agencies, and non-U.S. (foreign) organizations.

Are non-U.S. (foreign) organizations eligible?

Yes. The FOA includes non-U.S. (foreign) organizations among the explicitly highlighted eligible applicants.

What is the listed award ceiling?

The award ceiling is listed as $300,000.

What was the original closing date for this opportunity?

The original closing date is listed as 2022-09-22.

When was the opportunity first created?

The opportunity was first created on 2021-11-03.

What makes a project a good fit for this FOA based on the description?

A good fit is an emerging biospecimen technology with encouraging preliminary data that now needs refinement and rigorous validation, with a clear plan to demonstrate robustness and reliability under real-world conditions and to reduce pre-analytical variation or provide objective QA/QC measures for specimen quality.

What is the central focus of the biospecimen improvements supported here?

The central focus is improving quality, consistency, and downstream usefulness of biospecimens, especially by addressing pre-analytical factors that can degrade or alter analytes before analysis begins.